IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused biotechnology company, has dosed its first patient in the phase one combination study of IDE196 and binimetinib, an MEK inhibitor, intended to treat metastatic uveal melanoma (MUM), it was reported on Thursday.
The company is assessing the clinical combination of IDE196 and binimetinib, which is being provided by Pfizer based on a clinical trial collaboration and supply contract.
The company expects interim data from the MEK combination study in late 2021 to early 2022, when the firm will assess a potential registrational path for MUM and a potential collaboration.
GE HealthCare's Photonova Spectra gains FDA clearance
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
Aditxt acquires Ignite Proteomics to enhance cancer therapy selection
NASA awards Redwire USD4m to advance drug development in microgravity
Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate